Edition:
United Kingdom

Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

38.46USD
6:44pm BST
Change (% chg)

$1.08 (+2.89%)
Prev Close
$37.38
Open
$37.82
Day's High
$39.09
Day's Low
$37.53
Volume
64,050
Avg. Vol
153,705
52-wk High
$42.48
52-wk Low
$18.00

Summary

Name Age Since Current Position

Matthew Patterson

46 2018 Chairman of the Board, Chief Executive Officer

Natalie Holles

45 2018 President, Chief Operating Officer

Thomas Schuetz

57 2013 Co-Founder, Independent Director

Thomas Soloway

50 2019 Chief Financial Officer, Executive Vice President

Mark Meltz

2019 Senior Vice President, General Counsel

David Nagler

65 2015 Senior Vice President - Human Resources and Corporate Affairs

Eric Mosbrooker

52 2019 Senior Vice President and Chief Commercial Officer

Mary Newman

59 2014 Senior Vice President - Regulatory Affairs

Suyash Prasad

48 2014 Senior Vice President, Chief Medical Officer

Sarah Spencer

2019 Vice President, Corporate Communications

Louis Lange

69 2018 Lead Independent Director

Mark Goldberg

63 2017 Director

Jennifer Jarrett

48 2017 Director

Scott Morrison

60 2015 Independent Director

Julie Smith

47 2016 Independent Director

Andrew H. Chang

Director, Investor Relations

Biographies

Name Description

Matthew Patterson

Mr. Matthew (Matt) R. Patterson is Chairman of the Board, Chief Executive Officer of the Company. He has 20 years of experience in the research, development, and commercialization of innovative treatments for rare diseases and has held positions of senior management in both private and public biotechnology companies. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed Advisors. From 2004 to 2011, Mr. Patterson worked for Amicus Therapeutics, most recently serving as President and Acting Chief Executive Officer. Prior to his work at Amicus, from 1998 to 2004, he worked at BioMarin Pharmaceutical Inc., first serving as Vice President of Regulatory Affairs and later Vice President of Commercial Planning. From 1993 to 1998 Mr. Patterson worked at Genzyme Corporation in Manufacturing and Regulatory Affairs. Mr. Patterson is a member of the Board of Directors of Gilda's Club of New York City, which provides social and emotional support for people living with cancer. Mr. Patterson received his B.A. in Biochemistry from Bowdoin College.

Natalie Holles

Ms. Natalie C. Holles is President, Chief Operating Officer of the AUDENTES THERAPEUTICS, INC. She served as Senior Vice President, Corporate Development at Hyperion Therapeutics, Inc., a rare disease pharmaceutical company, from June 2013 through its acquisition by Horizon Pharma, plc in May 2015. From August 2012 until June 2013, Ms. Holles served as the Executive Vice President, Corporate Development at Immune Design, Inc., an immunotherapy company, and from December 2010 to June 2013, Ms. Holles served as an independent life sciences corporate development consultant. Earlier in her career, Ms. Holles served as the Vice President, Business Development at KAI Pharmaceuticals, Inc. and previously held corporate development and commercial roles at InterMune, Inc. and Genentech, Inc. Ms. Holles holds an A.B. from Stanford University and an M.A. from the University of Colorado, Boulder.

Thomas Schuetz

Dr. Thomas (Tom) J. Schuetz, M.D. Ph.D. serves as Co-Founder, Independent Director of the AUDENTES THERAPEUTICS, INC. . He is currently the Chief Executive Officer of Compass Therapeutics, LLC, a biotechnology company, where he has worked since July 2014. Previously, Dr. Schuetz was a consultant in the biotechnology industry from May 2012 to June 2014, including a consultant for us from July 2012 to June 2013. Prior to consulting, Dr. Schuetz was a venture partner at OrbiMed, a healthcare investment firm, where he worked from November 2007 to May 2012. Dr. Schuetz has also served as the Chief Medical Officer of Therion Biologics Corporation and the Vice President of Clinical Affairs at Transkaryotic Therapies, Inc. (now Shire Pharmaceuticals, Inc.). Dr. Schuetz has served as the Chief Medical Resident at Massachusetts General Hospital and completed a medical oncology fellowship at the Dana-Farber Cancer Institute. Dr. Schuetz also serves on the board of directors of a private company and previously served on the board of directors of Relypsa, Inc. Dr. Schuetz holds a B.S. from Xavier University, an M.D. from Harvard Medical School and a Ph.D. from Harvard University. Dr. Schuetz is Board Certified in Medical Oncology.

Thomas Soloway

Mr. Thomas P. Soloway is Chief Financial Officer, Executive Vice President of the company. he was Senior Vice President of the AUDENTES THERAPEUTICS, INC.Prior to joining us, Mr. Soloway served as the Senior Vice President, Chief Financial Officer of Ascendis Pharma A/S, a Danish biopharmaceutical company, from January 2014 until September 2015. Prior to Ascendis, Mr. Soloway co-founded Transcept Pharmaceuticals, Inc., a biotechnology company, in 2002. At Transcept, Mr. Soloway held various positions, including Chief Financial Officer and Executive Vice President, Chief Operating Officer. Prior to joining Transcept, Mr. Soloway financed and advised early stage healthcare and life sciences companies as a Principal at Montreux Equity Partners. Mr. Soloway holds a B.S. from the University of Southern California and an M.B.A. from Georgetown University.

Mark Meltz

Mr. Mark A. Meltz is Senior Vice President, General Counsel of the company. Mark has nearly 20 years of leadership experience serving in various roles at global pharmaceutical and biotechnology companies as well as a top international law firm. He joins Audentes from PaxVax, a specialty vaccines company, where he managed business development, legal, compliance, and government affairs/public policy functions, and led the company'sOctober 2018sale to Emergent BioSolutions. Prior to joining PaxVax, Mark worked at Biogen Idec (now Biogen), where he served as the U.S. commercial lead lawyer for Tysabri ® and Tecfidera ® (including for its US launch), and as the lead lawyer for global medical affairs. Earlier in his career, Mark served as Head of Legal for Novartis Vaccines forNorth AmericaandLatin America(including for the U.S. launch of Menveo ® ). Before joining the industry, Mark practiced law at the international law firm Bingham McCutchen LLP (now part ofMorgan Lewis& Bockius LLP), where he focused on mergers and acquisitions, venture capital financing, securities regulation, and general corporate matters. Mark earned his Juris Doctor fromBoston CollegeLaw School, Magna Cum Laude, and his Bachelor of Arts with Departmental Honors in Psychology from Yale University.

David Nagler

Mr. David Nagler is Senior Vice President - Human Resources and Corporate Affairs of the AUDENTES THERAPEUTICS, INC.Prior to joining us, he served as a human resources and corporate development consultant from April 2013 to February 2015. From July 2003 to March 2013, Mr. Nagler served as the Vice President Corporate Affairs at ARYx Therapeutics, Inc., a biotechnology company. He has also served as the Vice President Human Resources at Genentech, Inc. Mr. Nagler has served on the board of directors of U.C. Davis CONNECT, as well as the boards of the Northern California Chapter of the American Liver Foundation and the John Vasconcellos Legacy Project. Mr. Nagler studied at the University of California, Berkeley.

Eric Mosbrooker

Mr. Eric B. Mosbrooker is Senior Vice President and Chief Commercial Officer of the company. Mr. Mosbrooker has held numerous leadership roles throughout his more than 15 years in the healthcare industry, with the majority of his tenure focused on launching and commercializing treatments for rare and orphan diseases. Mr. Mosbrooker joins Audentes from Origin Biosciences, a subsidiary of BridgeBio Pharma and a biotechnology company focused on developing a treatment for molybdenum cofactor deficiency (MoCD) type A, a rare pediatric metabolic disorder, where he served as Chief Operating Officer. Prior to Origin Biosciences, Mr. Mosbrooker led the orphan business at Horizon Pharma after its acquisition of Raptor Pharmaceuticals. At Raptor, he was the Senior Vice President of Americas &Asia Pacific, where he led the U.S. launch of PROCYSBI ® , a drug for the treatment of nephropathic cystinosis. Previously, Mr. Mosbrooker served as the lead for commercial operations and market access for STRENSIQ ® at Alexion and Enobia Pharma, Inc. He also served in various commercial operational capacities at Onyx Pharmaceuticals, Jazz Pharmaceuticals Inc., Chiron Corporation (now Novartis), and Millennium Pharmaceuticals. Mr. Mosbrooker earned his B.S. in industrial engineering from theUniversity of Wisconsin, Madison.

Mary Newman

Ms. Mary Newman is Senior Vice President - Regulatory Affairs of the AUDENTES THERAPEUTICS, INC.. Prior to joining us, Ms. Newman held various positions at SARcode Biotherapeutics Inc., a biotechnology company, from July 2007 to April 2013, including as the Senior Vice President, Regulatory Affairs and Quality. She has also served in various management roles at BioMarin Pharmaceutical, Inc., Berlex Inc. (now Bayer HealthCare Pharmaceuticals Inc.) and Sequus Pharmaceuticals, Inc. (now Johnson and Johnson). Ms. Newman holds a B.S. from Oregon State University.

Suyash Prasad

Dr. Suyash Prasad was Senior Vice President, Chief Medical Officer of the Company.Prior to joining us, Dr. Prasad served as Senior Group Medical Director, Development Sciences at BioMarin Pharmaceutical, Inc., a rare genetic disease biotechnology company, from December 2010 to February 2014. Prior to joining BioMarin, Dr. Prasad served as the Director Global Medical Affairs, Personalized Genetic Health at Genzyme Corporation, a genetic disease biotechnology company, from January 2009 to December 2010 and in a country Medical Director role at Genzyme prior to that. He has also served as a senior clinical research physician at Eli Lilly. Prior to these roles, Dr. Prasad worked as a Pediatrician at Pediatric centers of excellence in the UK and Australia. Dr. Prasad is also an elected Fellow to the Faculty of Pharmaceutical Medicine of the Royal College of Physicians, UK. Dr. Prasad holds a degree from the University of Newcastle-upon-Tyne, United Kingdom and a Diploma from the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom. Dr. Prasad is a United Kingdom board certified physician and is a member of the Royal College of Physicians and the Royal College of Paediatrics and Child Health.

Sarah Spencer

Ms. Sarah Spencer is Vice President, Corporate Communications of the company. Sarah has more than 20 years of experience in healthcare and life sciences communications. She joins Audentes from GlaxoSmithKline (GSK) where she was most recently Head, US Corporate Communications. Sarah spent 13 years at GSK working in a variety of global communications roles both in the UK and the US where she had responsibility for corporate media relations, financial communications, crisis communications, reputation management, and product and pipeline communications. Sarah has worked directly with CEO & C-suite executives extensively. Prior to GSK, Sarah worked at Elan Pharmaceuticals (now Perrigo Company) where she led the launch communications for Tysabri ® and helped to build the profile of the company's neurology pipeline. Sarah also worked at Berry PR, a healthcare public relations agency, where she developed and executed communications strategies and campaigns for small and emerging biotech clients. Sarah began her career at Rite Aid Corporation where she served for eight years as a lead media spokesperson handling numerous high-profile issues and crises. Sarah holds a B.S. in Communications & Psychology from the State University of New York at Buffalo.

Louis Lange

Dr. Louis G. Lange, M.D. Ph.D.is a Lead Independent Director of the Company. He is also a general partner at Asset Management Ventures, an investment firm, where he has worked since June 2009. Dr. Lange was the co-founder and served as the President and Chief Executive Officer of Cardiogen Sciences, Inc., a biotechnology company, from April 2014 until it was acquired by us in August 2015. Dr. Lange also co-founded CV Therapeutics, Inc. in 1990 and served as the Chairman, Chief Executive Officer and Chief Scientific Officer until it was acquired by Gilead Sciences, Inc. in 2009. Dr. Lange has also served as the Chief of Cardiology and Professor of Medicine at Jewish Hospital at Washington University. Dr. Lange served on the board of directors of Maxygen, Inc. from December 2005 to August 2013, CymaBay Therapeutics, Inc. from November 2003 to October 2015, and Esperion Therapeutics, Inc. from February 2010 to May 2014. Dr. Lange also serves as a member of the Board of Trustees at the University of Rochester, The Gladstone Foundation, is a senior advisor to Gilead and was on the board of directors of BIO (the trade organization of biotech companies) from 1998 to 2009, as well as other private companies. Dr. Lange holds a B.A. from the University of Rochester, an M.D. from Harvard Medical School and a Ph.D. from Harvard University.

Mark Goldberg

Dr. Mark Goldberg, M.D is a directors of the AUDENTES THERAPEUTICS, INC. since December 2017. Dr. Goldberg holds an A.B. from Harvard College and an M.D. from Harvard Medical School.Our board of directors believes that Dr. Goldberg’s extensive experience in oncology, rare disease and gene therapy development and the biotechnology industry qualifies him to serve on our board of directors.

Jennifer Jarrett

Ms. Jennifer Jarrett is a directors AUDENTES THERAPEUTICS, INC. since June 2017. Ms. Jarrett has served as the Chief Financial and Business Officer of Arcus Biosciences, Inc., an immunotherapy biopharmaceutical company, since June 2017. Previously, Ms. Jarrett served as Chief Financial Officer of Medivation, Inc., a small molecule biopharmaceutical company, from April 2016 until the company’s purchase by Pfizer, Inc. in September 2016. Prior to Medivation, Ms. Jarrett served as Managing Director at Citigroup from July 2010 to April 2016, where she was responsible for building and managing Citigroup’s West Coast life sciences investment banking practice. Prior to Citigroup, Ms. Jarrett was a Managing Director in Credit Suisse’s Health Care Group focused on the biotechnology sector. Ms. Jarrett also serves on the board of directors of Arena Pharmaceuticals. She earned a B.A. in economics, cum laude, from Dartmouth College and holds an M.B.A. from the Stanford Graduate School of Business. Our board of directors believes that Ms. Jarrett should serve as a director due to her extensive experience in the life science industry and financial management of life science companies.

Scott Morrison

Mr. Scott W. Morrison is an Independent Director of the AUDENTES THERAPEUTICS, INC. From 1996 to December 2015, Mr. Morrison was a partner with Ernst & Young LLP, a public accounting firm, where he also served as U.S. Life Sciences Leader from 2002 to December 2015. Mr. Morrison serves on the board and chairs the audit committees of Global Blood Therapeutics Inc. and Corvus Pharmaceuticals, Inc. Mr. Morrison has held roles on the boards of directors of numerous life sciences industry organizations, including the Biotechnology Institute, the Life Sciences Foundation, the Bay Area Biosciences Association and the Emerging Companies Section of the Biotechnology Innovation Organization. He holds a B.S. from the University of California-Berkeley and is a certified public accountant (inactive).

Julie Smith

Ms. Julie Smith is an Independent Director of the AUDENTES THERAPEUTICS, INC. Most recently, Ms. Smith served as the Chief Executive Officer at Raptor Pharmaceutical Corp., a biopharmaceutical company she joined in September 2012. Prior to joining Raptor, Ms. Smith served as the Chief Commercial Officer at Enobia Pharma Corp. from July 2008 to May 2012. Earlier in her career, Ms. Smith served as Vice President, Commercial at Jazz Pharmaceuticals PLC, and held corporate commercial and policy roles at Genzyme General, Novazyme Pharmaceuticals Inc. and Bristol-Myers Squibb. Ms. Smith holds a B.S. from Cornell University.

Andrew H. Chang